Nautilus Biotechnology, Inc.

Good day and thank you for standing by. Welcome to the Nautilus Biotechnology first quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Gianni, Investor Relations. Please go ahead.

Thank you. Earlier today, Nautilus Biotechnology released financial results for the quarter ended March 31, 2026. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujal Patel, co-founder and CEO, Harag Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast on April 28, 2026. With that, I'll turn the call over to Sujal.

Thanks, Gian, and thank you all for joining us today. Before turning to the quarter, I'd like to begin by recapping the Q1 announcements we highlighted on our last earnings call. At that time, we discussed the launch of our Iterative Mapping Early Access Program in January, the debut of the Voyager platform to the proteomics community at USHUPO in St. Louis, Missouri, and our announcement of a collaboration with the Michael J. Fox Foundation and Weill Cornell Medicine Qatar to advance development of an alpha-synuclein proteoform assay for Parkinson's disease. We also highlighted our progress moving into the later stages of our broad-scale assay configuration change and our plans to make 2026 a pivotal year focused on commercialization. We also outlined a series of key milestones for 2026, including progressing early access customers into active TAO services projects, expanding early access in the second half of the year to include a second proteoform assay focused on an oncology target, introducing broad scale capabilities into early access later in 2026, and placing Voyager instruments externally through beta deployments. We also said we expect to initiate our commercial launch in late 2026 by opening the platform for pre-orders with customer installations beginning in early 2027. This would be followed by general availability of broad scale capabilities in the first half of 2027. This quarter, I'm pleased to say we are executing well against that roadmap. Today, we'll discuss the meaningful steps we've taken toward commercialization, including building out our commercial team and growing customer engagement in the early access program. We'll also cover the scientific and technical progress we've made across our iterative mapping assay portfolio, as well as how we continue to manage our resources prudently while investing in the opportunities ahead. A key priority for 2026 has been building the commercial organization needed to support launch activities. During the quarter, we welcomed Amber Faust as our VP of Global Sales, and we have since hired two additional sales team members. These are experienced industry veterans thoughtfully selected for their expertise and commitment to the field of proteomics, and we're excited about the depth of expertise they bring. With this team in place, we believe we are well positioned to engage prospective customers ahead of our commercial launch. Building on the successful launch of our iterative mapping early access program in January, we're pleased to report growing momentum in customer interest for the TAO assay and for custom assay development. Inbound interest has been steady and broad-based, spanning academic centers, nonprofit research institutions, and biopharma organizations. Today, we're excited to reiterate that last month, we announced our first named EAP customer, Baylor College of Medicine. Combined with our existing collaborations, we're pleased to be working with several academic institutions with deep expertise in proteomics and disease research. This is a meaningful milestone. We believe that it reflects the excitement top tier institutions are placing in the Voyager platform and marks an important step in translating our development progress into active, real-world scientific partnerships. While these early engagements are not intended to drive near-term revenue, they are designed to enable real biological discovery, support publications and grant applications, and ensure our workflows and data outputs align closely with customer needs. Importantly, we are beginning to receive requests to expand similar offerings into oncology-focused targets as well. What has been particularly encouraging is the quality of customer engagement we are observing. Researchers are increasingly recognizing how Nautilus' single molecule analysis of proteoforms and proteomes produces unique and highly differentiated data. We view this data as critically important across a variety of biological questions and also as a powerful foundation for training next generation AI models. Taken together, we believe these developments represent meaningful steps towards commercialization and reinforce our confidence that we have a highly differentiated platform and are addressing important unmet needs in the market. On the technology front, we continue to make progress advancing the core Voyager platform designed to execute a diverse family of iterative mapping-based assays. On the targeted proteoform assay front, we move forward with our oncology proteoform target down selection process, narrowing our focus to the highest priority candidates for our next early access program expansion. On the broad scale front, we continue to advance our assay configuration changes and improve assay performance. Parag will walk through these technical updates in more depth. With that, I'll turn the call over to Parag.